Arbutus Biopharma Corp (ABUS)

2.480
+0.150(+6.44%)
After Hours
2.470
-0.010(-0.403%)
- Real-time Data
  • Volume:
    1,012,375
  • Day's Range:
    2.260 - 2.510
  • 52 wk Range:
    1.850 - 4.670

ABUS Overview

Prev. Close
2.33
Day's Range
2.26-2.51
Revenue
36.11M
Open
2.3
52 wk Range
1.85-4.67
EPS
-0.477
Volume
1,012,375
Market Cap
371.88M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
899,939
P/E Ratio
-5.54
Beta
2.2
1-Year Change
-40.24%
Shares Outstanding
149,950,606
Next Earnings Date
09 Mar 2023
What is your sentiment on Arbutus Biopharma?
or
Market is currently closed. Voting is open during market hours.

Arbutus Biopharma Corp News

Arbutus Biopharma Corp Company Profile

Arbutus Biopharma Corp Company Profile

Employees
86

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company’s research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyBuyNeutralSell
Technical IndicatorsSellStrong BuyStrong BuyStrong SellStrong Sell
SummaryNeutralStrong BuyStrong BuySellStrong Sell
  • yep!
    0
    • Bulish
      0